Spherix Global Insights

April 05, 2023

U.S. Neurologists Cautiously Optimistic Following Accelerated Approval and Launch of Eisai/Biogen’s Leqembi for Early Alzheimer’s Disease, According to Spherix Global Insights

Concerns about ARIA and the associated monitoring requirements for Leqembi could present significant barriers to uptake.    

Exton, PA., April 5, 2023 – With the accelerated approval on January 6, 2023 for early Alzheimer’s disease, Eisai/Biogen’s Leqembi (lecanemab-irmb) became only the second approved disease-modifying therapy (DMT) for early Alzheimer’s disease.

Leqembi’s predecessor, Biogen’s Aduhelm (aducanumab-avwa), was the source of a controversial approval in June 2021, ultimately resulting in CMS’ subsequent refusal to cover anti-amyloid monoclonal antibodies (mAbs) approved under the accelerated pathway outside of a clinical trial.  As such, Leqembi entered into a fraught market, albeit one with little competition.

Neurologists (n=73) surveyed by Spherix Global Insights in March 2023 report receptivity to Leqembi, with a healthy proportion of survey respondents already prescribing the brand one month after commercial availability. However, most intend to wait until the drug receives traditional approval before initial trial, meaning broader uptake will be delayed until after the official July 6 PDUFA date. Should such approval be granted, nearly all respondents expect to prescribe the brand, with most starting in the first year following traditional approval. While the current share of Leqembi is low, neurologists expect growth to more than triple in the next six months, forecasting a much higher peak share, and underscoring the nascent demand in this market.

Despite immediate positive reactions post-approval, the side-effect profile of Leqembi, specifically amyloid-related imaging abnormalities (ARIA), and the associated monitoring required may hinder uptake of the DMT. Indeed, most neurologists express at least moderate concern regarding ARIA in Leqembi-treated patients, with only a minority believing that the benefits of the DMT outweigh the risks of ARIA.

As one interviewed neurologist summarized ARIA-related concerns, “Every time a patient has a complaint, you’re going to be saying, ‘Do I need to scan them? Do I need the MRI? Is it ARIA?’”

According to respondents, the serial MRIs required in the first few months of Leqembi treatment, the monitoring burden associated with the drug may indeed limit the number of patients neurologists can manage on the DMT.

One tool that could help ease the burden associated with Leqembi prescribing would be easier-to-use diagnostics, specifically a blood-based Alzheimer’s test. In fact, only a minority of neurologists are currently using the few blood-based amyloid assays available, they predict a substantial increase in use in the future. With the recently announced partnership between Roche and Eli Lilly for Roche’s Elecsys Amyloid Plasma Panel (EAPP), the market may soon have another option to facilitate diagnosis.

Spherix will cover the early Alzheimer’s disease market through multiple services in 2023, including tracking the launches of Leqembi and Eli Lilly’s donanemab, should they receive traditional approval later this year, through Spherix’s Launch Dynamix service.

Click Here to View Spherix’s 2023 Early Alzheimer’s Disease Publications

About Special Topix™

Special Topix™ is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

About Spherix Global Insights

Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry. The company’s unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers.

A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn and Twitter.


Spherix Global Insights Contacts

Emma McFadden, Senior Insights Director, Neurology
[email protected]

Scott Upham, Corporate Communications
[email protected]

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement by any company, brand, or product aforementioned.